Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.
Pennell DJ, et al. Among authors: porter jb.
Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22.
Haematologica. 2012.
PMID: 22271905
Free PMC article.
Clinical Trial.